ArticleTargeted oncology2025

Real-World Outcomes of Ipilimumab Plus Nivolumab for Metastatic Renal Cell Carcinoma: A National Population-Based Cohort Study.

Chin Hang Yiu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.